Literature DB >> 22669318

Characterization of malleability and immunological properties of human adenovirus type 3 hexon hypervariable region 1.

Tianhua Zhong1, Xiao Li, Zhichao Zhou, Ting Li, Xingui Tian, Rong Zhou.   

Abstract

Adenovirus (Ad) capsids that display exogenous epitopes can be potently immunogenic, eliciting a potent humoral response against components of the capsid. We used the epitopes flag, his(6)flag, his(6)lgsflag and AdV4HVR5 as model antigens to characterize the hexon hypervariable region (HVR) 1 as a site for epitope insertion. A peptide of up to 17 amino acids could be incorporated into HVR1 of the Ad3 hexon without adversely affecting the biological characteristics of the virus. Multiple vaccinations with capsid-modified Ad3 induced a humoral response against the epitope inserted in HVR1. However, antiserum against the his(6)flag or his(6)lgsflag epitope did not recognize glutathione S-transferase (GST)-his(6) and GST-flag fusion protein. Our study illustrates that there is an immune response against the new epitope within the amino acids of his(6)flag or his(6)lgsflag epitopes. This discovery could be a warning for the generation of multivalent vaccine vectors by incorporation of multiple epitopes into single HVRs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22669318     DOI: 10.1007/s00705-012-1364-1

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  3 in total

1.  Human Adenovirus Serotype 3 Vector Packaged by a Rare Serotype 14 Hexon.

Authors:  Xiaobo Su; Xingui Tian; Zaixue Jiang; Qiang Ma; Qian Liu; Xiaomei Lu; Rong Zhou
Journal:  PLoS One       Date:  2016-06-21       Impact factor: 3.240

2.  Identification and Application of Neutralizing Epitopes of Human Adenovirus Type 55 Hexon Protein.

Authors:  Xingui Tian; Qiang Ma; Zaixue Jiang; Junfeng Huang; Qian Liu; Xiaomei Lu; Qingming Luo; Rong Zhou
Journal:  Viruses       Date:  2015-10-27       Impact factor: 5.048

3.  Using multivalent adenoviral vectors for HIV vaccination.

Authors:  Linlin Gu; Zan C Li; Alexandre Krendelchtchikov; Valentina Krendelchtchikova; Hongju Wu; Qiana L Matthews
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.